SCHEMBL2641646

SCHEMBL2641646

CNC(=O)c1cc(-c2cnn([C@H]3CC[C@H](O)CC3)c2)ccc1Nc1nc(Nc2ccc(C[PH](=O)O)cc2)ncc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 6/20 0.42
▸ PTK2 Q05397 11/20 0.41
▸ KDR P35968 2/20 0.40
▸ KIT P10721 1/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ PTK2B Q14289 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ LRRK2 Q5S007 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2641645 1.00 FGFR1 (0.42) FGFR1PTK2KDRKITFLT3
SCHEMBL14767907 0.90 FGFR1 (0.42) FGFR1PTK2KDRKITFLT3
SCHEMBL14767909 0.90 FGFR1 (0.42) FGFR1PTK2KDRKITFLT3
SCHEMBL12974574 0.87 PTK2 (0.50) FGFR1PTK2KDRJAK2NTRK1
SCHEMBL2035830 0.87 PTK2 (0.50) FGFR1PTK2KDRJAK2NTRK1
SCHEMBL2035834 0.86 PTK2 (0.43) FGFR1PTK2KDRKITFLT3
SCHEMBL2636964 0.84 FGFR1 (0.42) FGFR1PTK2KDRJAK2NTRK1
SCHEMBL12586772 0.81 PTK2 (0.51) FGFR1PTK2KDRJAK2NTRK1
SCHEMBL2035153 0.80 PTK2 (0.44) FGFR1PTK2KDRJAK2NTRK1
SCHEMBL31260496 0.78 KDR (0.53) FGFR1PTK2KDRJAK2NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2438056-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI Pharmaceuticals, LLC (US) 2012-04-11 — — EP disclosed
WO-2010141406-A2 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2010-12-09 — — WO disclosed
Send feedback